Reville, Patrick K. http://orcid.org/0000-0001-8433-3360
Kantarjian, Hagop M. http://orcid.org/0000-0002-1908-3307
Ravandi, Farhad
Jabbour, Elias
DiNardo, Courtney D. http://orcid.org/0000-0001-9003-0390
Daver, Naval
Pemmaraju, Naveen
Ohanian, Maro
Alvarado, Yesid
Xiao, Lianchun
Alatrash, Gheath
Loghavi, Sanam
Rausch, Caitlin R. http://orcid.org/0000-0002-4166-5717
Borthakur, Gautam http://orcid.org/0000-0001-7679-6453
Konopleva, Marina http://orcid.org/0000-0002-9347-2212
Cortes, Jorge http://orcid.org/0000-0002-8636-1071
Kadia, Tapan M. http://orcid.org/0000-0002-9892-9832
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (T32CA009666)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA100632)
UT | University of Texas MD Anderson Cancer Center
Article History
Received: 22 September 2020
Revised: 6 February 2021
Accepted: 10 February 2021
First Online: 17 March 2021
Conflict of interest
: HMK: Consulting/honorarium: AbbVie, Actinium (Advisory Board), Agios, Amgen, Immunogen, Pfizer. Research Grants: AbbVie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi-Sankyo, Immunogen, Jazz Pharma, Novartis, Pfizer. FR: Research funding and member of advisory boards from BMS. EJ: Research grants and consultancy from Abbvie, Adaptive biotechnology, Amgen, BMS, Genentech, Pfizer, and Takeda. CDD: Research grants (to institution): Abbvie, Agios, Calithera, Celgene, Daiichi-Sankyo. Consultant/Advisory Boards: Abbvie, Agios, Celgene, Daiichi Sankyo, ImmuneOnc, Novartis, Takeda, Notable Labs. ND: Consulting/honorarium: BMS, Novartis, Jazz, Daiichi-Sankyo, Astellas, Abbvie, Genentech, Immunogen, Trillium, Forty-Seven, Gilead, Syndax, Kite, Pfizer. Research grants: BMS, Pfizer, Abbvie, Genentech, Astellas, Daiichi-Sankyo, Immunogen, Novimmune, Trovagene, Amgen, Hanmi, Fate, Forty-Seven. NP: Consulting/honorarium: Celgene; Stemline; Incyte; Novartis; MustangBio; Roche Diagnostics, LFB, Pacylex, AbbVie; Research grants: Stemline; Novartis; AbbVie; Samus; Cellectis; Plexxikon; Daiichi-Sankyo; Affymetrix, SagerStrong Foundation. MK: Consulting/honorarium: AbbVie, Genentech, F. Hoffman La-Roche, Stemline Therapeutics, Amgen, Forty-Seven, Kisoji, Reata Pharmaceutical. Research grants: AbbVie, Genentech, F. Hoffman La-Roche, Stemline Therapeutics, Forty-Seven, Kisoji, Eli Lilly, Cellectis, Calithera, Ablynx, Agios, Ascentage, Astra Zeneca. JC: Consulting/honorarium: Novartis, Pfizer, BiopTah Holdings, Jazz, Takeda. Research grants: BMS, Novartis, Pfizer, Takeda, Jazz, Merus, Astellas, Amphivena, Celgene. TMK: Consulting/honorarium: Novartis, Abbvie, Genentech, Pfizer, JAZZ, Daiichi-Sankyo; Research grants: BMS, Celgene, Pfizer, Incyte, Genentech, Astra Zeneca, Amgen, Abbvie, JAZZ, Cellenkos, Cyclacel. P.K.R., M.O., Y.A., L.X., G.A., S.L., C.R.R., and G.B. all have no conflicts to disclose.